Hospital
Cibola General Hospital Corporation
Cibola General Hospital Corporation was paid $26.50M by Medicaid between Jan 2018 and Dec 2024, across 234 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoCIBOLA GENERAL HOSPITAL CORPORATION
GRANTS, NM 87020
GRANTS, NM 87020
33aNPI1780677039assigned 08/23/2005
33bProvider typeCritical Access Hospital
28Total paid$26.50M
24GClaims290,654
24DCodes billed234
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in New Mexico
Rank by total paid#3 of 6
Median peer was paid$15.48M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,779 | $3.10M | |
| 2019 | 27,760 | $1.91M | |
| 2020 | 18,903 | $1.53M | |
| 2021 | 28,389 | $2.69M | |
| 2022 | 50,431 | $5.16M | |
| 2023 | 75,780 | $7.54M | |
| 2024incomplete | 44,612 | $4.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 14,521 | 13,520 | $5.05M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 7,028 | 6,469 | $3.34M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.7% | 10,153 | 9,533 | $2.31M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.6% | 2,489 | 2,285 | $1.50M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 1,521 | 1,429 | $1.13M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 3,403 | 2,820 | $798K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 1,790 | 1,664 | $772K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.6% | 2,787 | 2,664 | $687K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 4,461 | 3,933 | $602K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 4,370 | 3,698 | $533K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 4,307 | 3,776 | $525K |
| J3490 | Unclassified drugs | 1.8% | 8,183 | 4,154 | $489K |
222 more codes
| 71045 | Radiologic examination, chest; single view | 1.6% | 3,465 | $431K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 3,422 | $421K |
| 80053 | Comprehensive metabolic panel | 1.6% | 17,973 | $416K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 4,630 | $404K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 573 | $340K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 2,835 | $329K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 3,413 | $302K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 18,541 | $291K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 2,167 | $282K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 4,150 | $272K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.0% | 1,161 | $266K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 5,379 | $239K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,895 | $229K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,166 | $210K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,493 | $173K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 496 | $162K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 728 | $153K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,562 | $149K |
| 73562 | <1% | 702 | $147K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,551 | $132K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 747 | $113K |
| 73610 | <1% | 447 | $103K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 121 | $100K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 249 | $99K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,884 | $96K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,197 | $93K |
| 87430 | <1% | 2,801 | $91K | |
| 84484 | <1% | 3,250 | $88K | |
| 73630 | <1% | 492 | $80K | |
| 73030 | <1% | 371 | $75K | |
| 83690 | <1% | 3,679 | $74K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 595 | $66K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 254 | $65K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,211 | $64K |
| 82077 | <1% | 1,417 | $61K | |
| 59025 | Fetal non-stress test | <1% | 191 | $59K |
| 76801 | <1% | 220 | $57K | |
| 73130 | <1% | 343 | $57K | |
| 87800 | <1% | 717 | $55K | |
| G0378 | Hospital observation service, per hour | <1% | 112 | $55K |
| 83605 | <1% | 2,053 | $54K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 588 | $52K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 656 | $52K |
| 87400 | <1% | 1,797 | $50K | |
| 80061 | Lipid panel | <1% | 2,233 | $49K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 198 | $49K |
| 76830 | Ultrasound, transvaginal | <1% | 194 | $47K |
| 90837 | Psychotherapy session, about an hour | <1% | 462 | $45K |
| 83880 | <1% | 958 | $43K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,124 | $43K |
| 94761 | <1% | 1,399 | $38K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 187 | $36K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 482 | $35K |
| 84703 | <1% | 1,798 | $33K | |
| 81015 | <1% | 5,238 | $32K | |
| 88160 | <1% | 372 | $32K | |
| 81001 | <1% | 3,377 | $31K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 6,049 | $30K |
| 73110 | <1% | 170 | $29K | |
| 87040 | <1% | 939 | $29K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 59 | $28K |
| 81025 | <1% | 1,795 | $28K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,251 | $27K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,414 | $25K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 130 | $25K |
| 83735 | <1% | 2,031 | $24K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,499 | $24K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,853 | $24K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,147 | $21K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,131 | $21K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,024 | $20K |
| 97161 | <1% | 302 | $19K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 67 | $19K |
| 86850 | <1% | 656 | $19K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 548 | $19K |
| 84702 | <1% | 589 | $19K | |
| 85027 | <1% | 1,640 | $19K | |
| 80143 | <1% | 339 | $17K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 206 | $16K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $16K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 406 | $15K |
| 85610 | <1% | 2,317 | $15K | |
| 86140 | <1% | 1,422 | $15K | |
| 85379 | <1% | 590 | $15K | |
| 80179 | <1% | 290 | $15K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 153 | $14K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,212 | $14K |
| 72100 | <1% | 62 | $13K | |
| 87070 | <1% | 799 | $13K | |
| 87088 | <1% | 756 | $13K | |
| 85730 | <1% | 1,082 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 424 | $12K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,018 | $12K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 126 | $11K |
| 86900 | <1% | 1,063 | $11K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 54 | $11K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 214 | $11K |
| 84439 | <1% | 712 | $11K | |
| 96376 | <1% | 291 | $11K | |
| 96367 | <1% | 116 | $9K | |
| 87081 | <1% | 1,206 | $9K | |
| 86803 | <1% | 389 | $9K | |
| 87807 | <1% | 442 | $9K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 26 | $9K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 424 | $9K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 84 | $8K |
| 74018 | <1% | 42 | $8K | |
| 86592 | <1% | 884 | $8K | |
| 87340 | <1% | 382 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 156 | $7K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,302 | $7K |
| 82150 | <1% | 559 | $7K | |
| 95800 | <1% | 13 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 88 | $7K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 81 | $7K |
| 70486 | <1% | 12 | $7K | |
| 82962 | <1% | 2,111 | $7K | |
| 83655 | <1% | 290 | $6K | |
| 82803 | <1% | 132 | $6K | |
| 85007 | <1% | 794 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,501 | $6K |
| 86769 | <1% | 98 | $6K | |
| 87186 | <1% | 360 | $6K | |
| 87590 | <1% | 190 | $5K | |
| 36600 | <1% | 133 | $5K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 189 | $5K |
| 87490 | <1% | 189 | $5K | |
| 90715 | <1% | 190 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 783 | $5K |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 208 | $5K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 15 | $5K |
| 82570 | <1% | 543 | $5K | |
| 81513 | <1% | 72 | $5K | |
| A9270 | Non-covered item or service | <1% | 1,851 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,195 | $4K |
| 86885 | <1% | 244 | $4K | |
| 97032 | <1% | 203 | $4K | |
| 74019 | <1% | 28 | $4K | |
| 82550 | <1% | 402 | $4K | |
| 73564 | <1% | 20 | $4K | |
| 87481 | <1% | 73 | $4K | |
| 90839 | <1% | 43 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 72 | $4K |
| 82746 | <1% | 144 | $4K | |
| 81002 | <1% | 720 | $4K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 248 | $4K |
| 82607 | <1% | 146 | $4K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 108 | $4K |
| 84100 | <1% | 338 | $4K | |
| 86762 | <1% | 161 | $4K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 39 | $4K |
| 73502 | <1% | 28 | $4K | |
| 83550 | <1% | 244 | $4K | |
| 80320 | <1% | 114 | $4K | |
| 76641 | <1% | 15 | $4K | |
| 86695 | <1% | 147 | $3K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 55 | $3K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 60 | $3K |
| 82043 | <1% | 340 | $3K | |
| 82728 | <1% | 144 | $3K | |
| 74022 | <1% | 13 | $3K | |
| 83540 | <1% | 269 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 44 | $3K |
| 86787 | <1% | 101 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $2K |
| 86901 | <1% | 300 | $2K | |
| 90461 | <1% | 87 | $2K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,035 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 179 | $2K |
| 90670 | <1% | 37 | $2K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 258 | $2K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 149 | $2K |
| A9150 | Non-prescription drugs | <1% | 1,331 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 534 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 33 | $2K |
| 90686 | <1% | 166 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 530 | $1K |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 128 | $1K |
| 20610 | <1% | 50 | $1K | |
| 82951 | <1% | 49 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 14 | $1K |
| 85018 | <1% | 210 | $1K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 15 | $1K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $1K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 27 | $1K |
| 97162 | <1% | 13 | $999.01 | |
| 85014 | <1% | 184 | $968.25 | |
| 87205 | <1% | 127 | $966.20 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 268 | $710.92 |
| 85651 | <1% | 83 | $695.04 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 109 | $661.54 |
| 82553 | <1% | 33 | $654.84 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 236 | $635.19 |
| 99173 | <1% | 18 | $510.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 269 | $481.17 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $462.99 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $441.18 |
| 99000 | <1% | 79 | $439.08 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 16 | $414.48 |
| 86308 | <1% | 27 | $345.90 | |
| 82105 | <1% | 13 | $335.96 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 42 | $330.51 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 99 | $316.21 |
| 80305 | <1% | 19 | $296.18 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 12 | $295.09 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 113 | $242.93 |
| 92552 | <1% | 17 | $213.85 | |
| 86709 | <1% | 14 | $209.76 | |
| 86705 | <1% | 13 | $197.56 | |
| 81000 | <1% | 104 | $194.94 | |
| J1815 | Injection, insulin, per 5 units | <1% | 94 | $181.80 |
| 83615 | <1% | 13 | $170.57 | |
| 82248 | <1% | 18 | $158.95 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 92 | $156.51 |
| 82010 | <1% | 12 | $153.44 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 19 | $94.55 |
| 96161 | <1% | 33 | $90.09 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 24 | $80.84 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 16 | $45.39 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 13 | $45.38 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 13 | $43.84 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 27 | $13.80 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROJAS, DONNA (CREDENTIALING SPECIALIST)
| Provider | Location | Paid |
|---|---|---|
| Cibola General Hospital Corporation | Grants, NM | $6.40M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.